Akoya Biosciences Inc. said an in-depth comparison of immuno-oncology biomarker types determined that multiplex immunofluorescence with spatial characterization significantly outperformed other biomarker testing approaches for predicting patient response to treatments targeting PD-1/PD-L1.
When President Donald Trump on Feb. 3 signed H.R.7148, a package funding most of the federal government through FY26, many in oncology released a long-held sigh of relief.
